Myasthenia Gravis

A new analysis has determined potential risk factors for developing myasthenia gravis following COVID-19 vaccination, with symptoms likely to appear within 2 weeks of receipt of a COVID-19 vaccine.

Qualitative interviews were conducted and a web-based quantitative survey was administered to have a clearer understanding of the economic impact of social determinants of health on patients living with generalized myasthenia gravis (gMG).

Patients with generalized myasthenia gravis treated with efgartigimod consistently exceeded treatment compared with placebo regardless of gender in age, disease duration, body mass index, and thymectomy.

Overactivation of the immune system is a potential serious adverse event (AE) following immune checkpoint inhibition (ICI) treatment for any of several cancers in the first and second line; among these AEs is myasthenia gravis.

Approximately 70 to 300 million individuals worldwide are living with myasthenia gravis, an antibody-mediated autoimmune disorder that adversely affects neuromuscular junction function.

Patient acceptable symptom state (PASS) may be a reliable indicator of long-term outcomes among patients who have myasthenia gravis (MG).

The highest proportions of patients with severe ocular impairment at baseline showed greater improvements in symptom severity on ravulizumab in comparison with placebo after 26 weeks.

The investigation evaluated if symptom signatures of myasthenia gravis exacerbations could be evaluated using real-world data gathered via a smartphone-based research platform.

With this study, investigators hoped to describe personality traits among individuals who have the autoimmune, neuromuscular disease.

Investigators say computer algorithms can be used to assess physical and vocal signs of myasthenia gravis (MG).

This study compared autoantigen detection of acetylcholine receptor and muscle-specific kinase, among 3 assays used in suspected cases of myasthenia gravis.

Study authors used data from the Taiwan National Healthcare Insurance Research database and Death Registry for their population-based retrospective cohort study.

Nearly half of patients treated with zilucoplan were considered responders on Myasthenia Gravis Activities of Daily Living (MG-ADL) at the first week, suggesting a rapid onset of efficacy.

Investigators conducted a case study of a patient who presented with COVID-19–induced seronegative myasthenia gravis, seeking more information on neurological manifestations of the respiratory disease.

Lymphoplasmapheresis (LPE) was also completed with fewer replacements compared with plasma exchange (PE) for myasthenia gravis (MG).

The patient was found to have Toxoplasma gondii, a parasitic infection, and died 5 months after his initial diagnosis.

However, few patients with nonthymomatous myasthenia gravis (NTMG) undergo this procedure, results suggest.

A real-world study of 5 European countries shows frequent misdiagnoses/delays in diagnosis, acute hospitalizations, and quality-of-life impairments.

The patient in this case experienced significant muscle weakness after emerging from anesthesia.

The rare autoimmune disorder generalized myasthenia gravis can cause muscle weakness in the limbs and face.

The treatment is the first approved by the FDA to treat the 2 most common subtypes of generalized myasthenia gravis.

Both complement inhibitors and neonatal Fc receptor blockers led to improvements in symptoms, according to a meta-analysis.

The scale is meant to better quantify how clusters of symptoms impact patients’ quality of life.

The majority of respondents living with generalized myasthenia gravis (MG) were not working, the results showed.

A new small case series finds higher rates of symptom flares in individuals who have muscle-specific tyrosine kinase (MuSK)–positive myasthenia gravis (MG) than previous research.

The training did not, however, affect postoperative limb skeletal muscle weakness or exercise capacity.

The findings support policies urging vaccination of individuals who have myasthenia gravis (MG).

A patient’s inability to count while holding their breath can be an indication of respiratory distress in myasthenia gravis.

Results from 2 late-stage trials evaluating generalized myasthenia gravis therapies indicated both drugs, rozanolixizumab and zilucoplan, have potential as targeted treatment options.

People with myasthenia gravis (MG) had a higher risk of hospitalization for COVID-19 compared to the general population and a control group of people with rheumatoid arthritis (RA).